{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T08:53:12Z","timestamp":1791276792717,"version":"4.1.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T00:00:00Z","timestamp":1791244800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T00:00:00Z","timestamp":1791244800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Bone Miner Metab"],"DOI":"10.1007\/s00774-026-01751-x","type":"journal-article","created":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T08:27:43Z","timestamp":1791275263000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Acute-phase reaction and fracture outcomes from zoledronic acid: a systematic review and meta-analysis"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7265-8579","authenticated-orcid":false,"given":"Masaki","family":"Takigawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazumasa","family":"Kotake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Tsuge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiro","family":"Saitsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichi","family":"Isaji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunsuke","family":"Kondo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoki","family":"Maruyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norio","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,6]]},"reference":[{"key":"1751_CR1","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1196\/annals.1346.041","volume":"1068","author":"RGG Russell","year":"2006","unstructured":"Russell RGG (2006) Bisphosphonates: from bench to bedside. Ann N Y Acad Sci 1068:367\u2013401. https:\/\/doi.org\/10.1196\/annals.1346.041","journal-title":"Ann N Y Acad Sci"},{"key":"1751_CR2","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1007\/s00198-007-0367-3","volume":"18","author":"JP Devogelaer","year":"2007","unstructured":"Devogelaer JP, Brown JP, Burckhardt P, Meunier PJ, Goemaere S, Lippuner K, Body JJ, Samsioe G, Felsenberg D, Fashola T, Sanna L, Ortmann CE, Trechsel U, Krasnow J, Eriksen EF, Garnero P\u00a0(2007) Zoledronic acid efficacy and safety over five years in postmenopausal osteoporosis. Osteoporos Int 18:1211\u20131218. https:\/\/doi.org\/10.1007\/s00198-007-0367-3","journal-title":"Osteoporos Int"},{"key":"1751_CR3","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1016\/S0140-6736(09)60250-6","volume":"373","author":"DM Reid","year":"2009","unstructured":"Reid DM, Devogelaer JP, Saag K, Roux C, Lau CS, Reginster JY, Papanastasiou P, Ferreira A, Hartl F, Fashola T, Mesenbrink P, Sambrook PN (2009) Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial. Lancet 373:1253\u20131263. https:\/\/doi.org\/10.1016\/S0140-6736(09)60250-6","journal-title":"Lancet"},{"key":"1751_CR4","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.1056\/NEJMoa074941","volume":"357","author":"KW Lyles","year":"2007","unstructured":"Lyles KW, Col\u00f3n-Emeric CS, Magaziner JS, Adachi JD, Pieper CF, Mautalen C, Hyldstrup L, Recknor C, Nordsletten L, Moore KA, Lavecchia C, Zhang J, Mesenbrink P, Hodgson PK, Abrams K, Orloff JJ, Horowitz Z, Eriksen EF, Boonen S\u00a0(2007) Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med 357:1799\u20131809. https:\/\/doi.org\/10.1056\/NEJMoa074941","journal-title":"N Engl J Med"},{"key":"1751_CR5","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1056\/NEJMoa1204061","volume":"367","author":"S Boonen","year":"2012","unstructured":"Boonen S, Reginster JY, Kaufman JM, Lippuner K, Zanchetta J et al (2012) Fracture risk and Zoledronic acid therapy in men with osteoporosis. N Engl J Med 367:1714\u20131723. https:\/\/doi.org\/10.1056\/NEJMoa1204061","journal-title":"N Engl J Med"},{"key":"1751_CR6","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/j.eprac.2021.02.001","volume":"27","author":"NB Watts","year":"2021","unstructured":"Watts NB, Camacho PM, Lewiecki EM, Petak SM, AACE\/ACE Postmenopausal Osteoporosis Guidelines Task Force (2021) American Association of Clinical Endocrinologists\/American College of Endocrinology Clinical practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis-2020 update. Endocr Pract 27:379\u2013380. https:\/\/doi.org\/10.1016\/j.eprac.2021.02.001","journal-title":"Endocr Pract"},{"key":"1751_CR7","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1007\/s11657-022-01061-5","volume":"17","author":"CL Gregson","year":"2022","unstructured":"Gregson CL, Armstrong DJ, Bowden J, Cooper C, Edwards J et al (2022) UK clinical guideline for the prevention and treatment of osteoporosis. Arch Osteoporos 17:58. https:\/\/doi.org\/10.1007\/s11657-022-01061-5","journal-title":"Arch Osteoporos"},{"key":"1751_CR8","doi-asserted-by":"publisher","first-page":"818","DOI":"10.7326\/M15-1361","volume":"166","author":"A Qaseem","year":"2017","unstructured":"Qaseem A, Forciea MA, McLean RM, Denberg TD, Barry MJ, Cooke M, Fitterman N, Harris RP, Humphrey LL, Kansagara D, McLean RM, Mir TP, Sch\u00fcnemann HJ\u00a0(2017) Treatment of low bone density or osteoporosis to prevent fractures in men and women: a clinical practice guideline update from the American College of Physicians. Ann Intern Med 166:818\u2013839. https:\/\/doi.org\/10.7326\/M15-1361","journal-title":"Ann Intern Med"},{"key":"1751_CR9","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1056\/NEJMoa067312","volume":"356","author":"DM Black","year":"2007","unstructured":"Black DM, Delmas PD, Eastell R, Reid IR, Boonen S et al (2007) Once-yearly Zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 356:1809\u20131822. https:\/\/doi.org\/10.1056\/NEJMoa067312","journal-title":"N Engl J Med"},{"key":"1751_CR10","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1517\/14656566.2011.537259","volume":"12","author":"G Baio","year":"2011","unstructured":"Baio G, Barbagallo M, D'Avola G, Di Luccio A, Di Tanna GL, Falaschi P, Iolascon G, Malavolta N, Robbiati F, Ulivieri FM\u00a0(2011) Improving adherence in osteoporosis: a new management algorithm for the patient with osteoporosis. Expert Opin Pharmacother 12:257\u2013268. https:\/\/doi.org\/10.1517\/14656566.2011.537259","journal-title":"Expert Opin Pharmacother"},{"key":"1751_CR11","doi-asserted-by":"publisher","first-page":"231","DOI":"10.2147\/PPA.S10917","volume":"4","author":"JD Ringe","year":"2010","unstructured":"Ringe JD (2010) Development of clinical utility of Zoledronic acid and patient considerations in the treatment of osteoporosis. Patient Prefer Adherence 4:231\u2013245. https:\/\/doi.org\/10.2147\/PPA.S10917","journal-title":"Patient Prefer Adherence"},{"key":"1751_CR12","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1177\/1078155207080806","volume":"13","author":"K Olson","year":"2007","unstructured":"Olson K, Van Poznak C (2007) Significance and impact of bisphosphonate-induced acute phase responses. J Oncol Pharm Pract 13:223\u2013229. https:\/\/doi.org\/10.1177\/1078155207080806","journal-title":"J Oncol Pharm Pract"},{"key":"1751_CR13","doi-asserted-by":"publisher","first-page":"6222s","DOI":"10.1158\/1078-0432.CCR-06-0843","volume":"12","author":"AJ Roelofs","year":"2006","unstructured":"Roelofs AJ, Thompson K, Gordon S, Rogers MJ (2006) Molecular mechanisms of action of bisphosphonates: current status. Clin Cancer Res 12:6222s\u20136230s. https:\/\/doi.org\/10.1158\/1078-0432.CCR-06-0843","journal-title":"Clin Cancer Res"},{"key":"1751_CR14","doi-asserted-by":"publisher","first-page":"2439","DOI":"10.1016\/j.jorganchem.2004.09.069","volume":"690","author":"JR Green","year":"2005","unstructured":"Green JR (2005) Zoledronic acid: pharmacologic profile of a potent bisphosphonate. J Organomet Chem 690:2439\u20132448. https:\/\/doi.org\/10.1016\/j.jorganchem.2004.09.069","journal-title":"J Organomet Chem"},{"key":"1751_CR15","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1002\/jbmr.5650100617","volume":"10","author":"DH Schweitzer","year":"1995","unstructured":"Schweitzer DH, Oostendorp-van de Ruit M, Van der Pluijm G, L\u00f6wik CW, Papapoulos SE (1995) Interleukin-6 and the acute phase response during treatment of patients with Paget\u2019s disease with the nitrogen-containing bisphosphonate dimethylaminohydroxypropylidene bisphosphonate. J Bone Miner Res 10:956\u2013962. https:\/\/doi.org\/10.1002\/jbmr.5650100617","journal-title":"J Bone Miner Res"},{"key":"1751_CR16","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/8756-3282(95)00448-3","volume":"18","author":"A Sauty","year":"1996","unstructured":"Sauty A, Pecherstorfer M, Zimmer-Roth I, Fioroni P, Juillerat L, Markert M, Ludwig H, Leuenberger P, Burckhardt P, Thiebaud D\u00a0(1996) Interleukin-6 and tumor necrosis factor alpha levels after bisphosphonates treatment in vitro and in patients with malignancy. Bone 18:133\u2013139. https:\/\/doi.org\/10.1016\/8756-3282(95)00448-3","journal-title":"Bone"},{"key":"1751_CR17","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1007\/s002239900353","volume":"61","author":"D Thi\u00e9baud","year":"1997","unstructured":"Thi\u00e9baud D, Sauty A, Burckhardt P, Leuenberger P, Sitzler L, Green JR, Kandra A, Zieschang J, Ibarra de Palacios P\u00a0(1997) An in vitro and in vivo study of cytokines in the acute-phase response associated with bisphosphonates. Calcif Tissue Int 61:386\u2013392. https:\/\/doi.org\/10.1007\/s002239900353","journal-title":"Calcif Tissue Int"},{"key":"1751_CR18","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1002\/jbmr.521","volume":"27","author":"M Rossini","year":"2012","unstructured":"Rossini M, Adami S, Viapiana O, Ortolani R, Vella A, Fracassi E, Gatti D.\u00a0(2012) Circulating \u03b3\u03b4 T cells and the risk of acute-phase response after Zoledronic acid administration. J Bone Miner Res 27:227\u2013230. https:\/\/doi.org\/10.1002\/jbmr.521","journal-title":"J Bone Miner Res"},{"key":"1751_CR19","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1007\/s00198-023-06803-w","volume":"34","author":"K Lu","year":"2023","unstructured":"Lu K, Wu YM, Shi Q, Gong YQ, Zhang T, Li C (2023) The impact of acute-phase reaction on mortality and re-fracture after Zoledronic acid in hospitalized elderly osteoporotic fracture patients. Osteoporos Int 34:1613\u20131623. https:\/\/doi.org\/10.1007\/s00198-023-06803-w","journal-title":"Osteoporos Int"},{"key":"1751_CR20","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1002\/jbmr.4434","volume":"37","author":"DM Black","year":"2022","unstructured":"Black DM, Reid IR, Napoli N, Ewing SK, Shiraki M, Nakamura T, Takeuchi Y, Schafer AL, Kim TY, Cauley JA\u00a0(2022) The interaction of acute-phase reaction and efficacy for osteoporosis after Zoledronic acid: HORIZON Pivotal Fracture Trial. J Bone Miner Res 37:21\u201328. https:\/\/doi.org\/10.1002\/jbmr.4434","journal-title":"J Bone Miner Res"},{"key":"1751_CR21","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1007\/s00223-021-00884-7","volume":"109","author":"M Shiraki","year":"2021","unstructured":"Shiraki M, Kuroda T, Takeuchi Y, Sugimoto T, Tanaka S, Suzuki H, Hiraishi K, Nakamura T\u00a0(2021) Acute phase reactions after intravenous infusion of Zoledronic acid in Japanese patients with osteoporosis: sub-analyses of the phase III ZONE study. Calcif Tissue Int 109:666\u2013674. https:\/\/doi.org\/10.1007\/s00223-021-00884-7","journal-title":"Calcif Tissue Int"},{"key":"1751_CR22","doi-asserted-by":"publisher","DOI":"10.1186\/s12891-024-07781-8","volume":"25","author":"Y Du","year":"2024","unstructured":"Du Y, Yu W, Gou H, Lei Y, Zhang T, Tang W, Chen M, Li H, Cheng Q\u00a0(2024) Change in body temperature, not acute-phase reaction, predict anti-osteoporosis efficacy after the first administration of zoledronic acid: a prospective observational cohort study. BMC Musculoskelet Disord 25:694. https:\/\/doi.org\/10.1186\/s12891-024-07781-8","journal-title":"BMC Musculoskelet Disord"},{"key":"1751_CR23","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1007\/s11657-020-00733-4","volume":"15","author":"A Sp\u00e5ngeus","year":"2020","unstructured":"Sp\u00e5ngeus A, Johansson S, Woisetschl\u00e4ger M (2020) Adherence to and persistence with zoledronic acid treatment for osteoporosis-reasons for early discontinuation. Arch Osteoporos 15:58. https:\/\/doi.org\/10.1007\/s11657-020-00733-4","journal-title":"Arch Osteoporos"},{"key":"1751_CR24","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.g7647","volume":"350","author":"L Shamseer","year":"2015","unstructured":"Shamseer L, Moher D, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle P, Stewart LA (2015) Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ 350:g7647. https:\/\/doi.org\/10.1136\/bmj.g7647","journal-title":"BMJ"},{"key":"1751_CR25","doi-asserted-by":"publisher","first-page":"2008","DOI":"10.1001\/jama.283.15.2008","volume":"283","author":"DF Stroup","year":"2000","unstructured":"Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, Moher D, Becker BJ, Sipe TA, Thacker SB\u00a0(2000) Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 283:2008\u20132012. https:\/\/doi.org\/10.1001\/jama.283.15.2008","journal-title":"JAMA"},{"key":"1751_CR26","doi-asserted-by":"publisher","first-page":"12","DOI":"10.6065\/apem.2346114.057","volume":"29","author":"HL Ferjani","year":"2024","unstructured":"Ferjani HL, Cherif I, Nessib DB, Kaffel D, Maatallah K, Hamdi W (2024) Pediatric and adult osteoporosis: a contrasting mirror. Ann Pediatr Endocrinol Metab 29:12\u201318. https:\/\/doi.org\/10.6065\/apem.2346114.057","journal-title":"Ann Pediatr Endocrinol Metab"},{"key":"1751_CR27","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1056\/NEJMoa011807","volume":"346","author":"IR Reid","year":"2002","unstructured":"Reid IR, Brown JP, Burckhardt P, Horowitz Z, Richardson P et al (2002) Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med 346:653\u2013661. https:\/\/doi.org\/10.1056\/NEJMoa011807","journal-title":"N Engl J Med"},{"key":"1751_CR28","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.bone.2007.03.011","volume":"41","author":"M McClung","year":"2007","unstructured":"McClung M, Recker R, Miller P, Fiske D, Minkoff J, Kriegman A, Zhou W, Adera M, Davis J\u00a0(2007) Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate. Bone 41:122\u2013128. https:\/\/doi.org\/10.1016\/j.bone.2007.03.011","journal-title":"Bone"},{"key":"1751_CR29","doi-asserted-by":"publisher","first-page":"4380","DOI":"10.1210\/jc.2010-0597","volume":"95","author":"IR Reid","year":"2010","unstructured":"Reid IR, Gamble GD, Mesenbrink P, Lakatos P, Black DM (2010) Characterization of and risk factors for the acute-phase response after zoledronic acid. J Clin Endocrinol Metab 95:4380\u20134387. https:\/\/doi.org\/10.1210\/jc.2010-0597","journal-title":"J Clin Endocrinol Metab"},{"key":"1751_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4158\/GL-2020-0524SUPPL","volume":"26","author":"PM Camacho","year":"2020","unstructured":"Camacho PM, Petak SM, Binkley N, Diab DL, Eldeiry LS, Farooki A, Harris ST, Hurley DL, Kelly J, Lewiecki EM, Pessah-Pollack R, McClung M, Wimalawansa SJ, Watts NB\u00a0(2020) American Association of Clinical Endocrinologists\/American College of Endocrinology Clinical practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis-2020 update. Endocr Pract 26:1\u201346. https:\/\/doi.org\/10.4158\/GL-2020-0524SUPPL","journal-title":"Endocr Pract"},{"key":"1751_CR31","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1007\/s00198-017-3992-5","volume":"28","author":"AW Popp","year":"2017","unstructured":"Popp AW, Senn R, Curkovic I, Senn C, Buffat H, Popp PF, Lippuner K\u00a0(2017) Factors associated with acute-phase response of bisphosphonate-na\u00efve or pretreated women with osteoporosis receiving an intravenous first dose of zoledronate or ibandronate. Osteoporos Int 28:1995\u20132002. https:\/\/doi.org\/10.1007\/s00198-017-3992-5","journal-title":"Osteoporos Int"},{"key":"1751_CR32","doi-asserted-by":"publisher","first-page":"1838","DOI":"10.1002\/art.21918","volume":"54","author":"PD Delmas","year":"2006","unstructured":"Delmas PD, Adami S, Strugala C, Stakkestad JA, Reginster JY, Felsenberg D, Christiansen C, Civitelli R, Drezner MK, Recker RR, Bolognese M, Hughes C, Masanauskaite D, Ward P, Sambrook P, Reid DM\u00a0(2006) Intravenous ibandronate injections in postmenopausal women with osteoporosis: one-year results from the dosing intravenous administration study. Arthritis Rheum 54:1838\u20131846. https:\/\/doi.org\/10.1002\/art.21918","journal-title":"Arthritis Rheum"},{"key":"1751_CR33","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1016\/j.jocd.2019.07.001","volume":"22","author":"CR Shuhart","year":"2019","unstructured":"Shuhart CR, Yeap SS, Anderson PA, Jankowski LG, Lewiecki EM, Morse LR, Rosen HN, Weber DR, Zemel BS, Shepherd JA (2019) Executive summary of the 2019 ISCD Position Development Conference on Monitoring Treatment, DXA Cross-calibration and Least Significant Change, Spinal Cord Injury, Peri-prosthetic and Orthopedic Bone Health, Transgender Medicine, and Pediatrics. J Clin Densitom 22:453\u2013471. https:\/\/doi.org\/10.1016\/j.jocd.2019.07.001","journal-title":"J Clin Densitom"},{"key":"1751_CR34","doi-asserted-by":"publisher","first-page":"280","DOI":"10.7326\/0003-4819-158-4-201302190-00009","volume":"158","author":"JA Hayden","year":"2013","unstructured":"Hayden JA, van der Windt DA, Cartwright JL, C\u00f4t\u00e9 P, Bombardier C (2013) Assessing bias in studies of prognostic factors. Ann Intern Med 158:280\u2013286. https:\/\/doi.org\/10.7326\/0003-4819-158-4-201302190-00009","journal-title":"Ann Intern Med"},{"key":"1751_CR35","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.jclinepi.2019.12.023","volume":"121","author":"F Foroutan","year":"2020","unstructured":"Foroutan F, Guyatt G, Zuk V, Vandvik PO, Alba AC, Mustafa R, Vernooij R, Arevalo-Rodriguez I, Munn Z, Roshanov P, Riley R, Schandelmaier S, Kuijpers T, Siemieniuk R, Canelo-Aybar C, Schunemann H, Iorio A.\u00a0(2020) GRADE Guidelines 28 GRADE Guidelines 28: use of GRADE for the assessment of evidence about prognostic factors: rating certainty in identification of groups of patients with different absolute risks. J Clin Epidemiol 121:62\u201370. https:\/\/doi.org\/10.1016\/j.jclinepi.2019.12.023","journal-title":"J Clin Epidemiol"},{"key":"1751_CR36","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1002\/jbmr.1494","volume":"27","author":"DM Black","year":"2012","unstructured":"Black DM, Reid IR, Boonen S, Bucci-Rechtweg C, Cauley JA, Cosman F, Cummings SR, Hue TF, Lippuner K, Lakatos P, Leung PC, Man Z, Martinez RL, Tan M, Ruzycky ME, Su G, Eastell R\u00a0(2012) The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT). J Bone Miner Res 27:243\u2013254. https:\/\/doi.org\/10.1002\/jbmr.1494","journal-title":"J Bone Miner Res"},{"key":"1751_CR37","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1002\/jbmr.2442","volume":"30","author":"DM Black","year":"2015","unstructured":"Black DM, Reid IR, Cauley JA, Cosman F, Leung PC, Lakatos P, Lippuner K, Cummings SR, Hue TF, Mukhopadhyay A, Tan M, Aftring RP, Eastell R\u00a0(2015) The effect of 6 versus 9 years of Zoledronic acid treatment in osteoporosis: a randomized second extension to the HORIZON-Pivotal Fracture Trial (PFT). J Bone Miner Res 30:934\u2013944. https:\/\/doi.org\/10.1002\/jbmr.2442","journal-title":"J Bone Miner Res"},{"key":"1751_CR38","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1111\/j.1532-5415.2009.02673.x","volume":"58","author":"S Boonen","year":"2010","unstructured":"Boonen S, Black DM, Col\u00f3n-Emeric CS, Eastell R, Magaziner JS, Eriksen EF, Mesenbrink P, Haentjens P, Lyles KW\u00a0(2010) Efficacy and safety of a once-yearly intravenous zoledronic acid 5 mg for fracture prevention in elderly postmenopausal women with osteoporosis aged 75 and older. J Am Geriatr Soc 58:292\u2013299. https:\/\/doi.org\/10.1111\/j.1532-5415.2009.02673.x","journal-title":"J Am Geriatr Soc"},{"key":"1751_CR39","doi-asserted-by":"publisher","first-page":"9492883","DOI":"10.1155\/2021\/9492883","volume":"2021","author":"BSA Ferreira","year":"2021","unstructured":"Ferreira BSA, da Cunha BM, Valadares LP, Moreira LA, Batista FGA, Hottz CDF, Lins MMP, Magalh\u00e3es GGR, de Arruda LM, Ramalho SHR\u00a0(2021) Characteristics associated with acute-phase response following first Zoledronic acid infusion in Brazilian population with osteoporosis. J Osteoporos 2021:9492883. https:\/\/doi.org\/10.1155\/2021\/9492883","journal-title":"J Osteoporos"},{"key":"1751_CR40","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1007\/s00774-021-01221-6","volume":"39","author":"Y Nakamura","year":"2021","unstructured":"Nakamura Y, Shimizu T, Asano T, Shimodan S, Ishizu H, Takahashi D, Takahata M, Iwasaki N\u00a0(2021) Short-term efficacy and safety of zoledronate acid or denosumab in Japanese patients with postmenopausal osteoporosis. J Bone Miner Metab 39:824\u2013832. https:\/\/doi.org\/10.1007\/s00774-021-01221-6","journal-title":"J Bone Miner Metab"},{"key":"1751_CR41","doi-asserted-by":"publisher","unstructured":"Takigawa M, Yamamoto N, Kotake K, Tsuge T, Saitsu A, Isaji Y, Kondo S, Maruyama T (2025), Acute phase reactions after zoledronic acid administration on fracture incidence and changes in bone mineral density and bone turnover markers in osteoporosis patients: a single-center retrospective cohort study. Open science framework. Preprint. https:\/\/doi.org\/10.17605\/OSF.IO\/K89XU","DOI":"10.17605\/OSF.IO\/K89XU"},{"key":"1751_CR42","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.jclinepi.2020.11.017","volume":"131","author":"P Jia","year":"2020","unstructured":"Jia P, Lin L, Kwong JSW, Xu C (2020) Many meta-analyses of rare events in the Cochrane database of systematic reviews were underpowered. J Clin Epidemiol 131:113\u2013122. https:\/\/doi.org\/10.1016\/j.jclinepi.2020.11.017","journal-title":"J Clin Epidemiol"},{"key":"1751_CR43","doi-asserted-by":"publisher","first-page":"879","DOI":"10.2217\/imt.13.77","volume":"5","author":"AL de Ara\u00fajo","year":"2013","unstructured":"de Ara\u00fajo AL, Silva LCR, Fernandes JR, Benard G (2013) Preventing or reversing immunosenescence: can exercise be an immunotherapy? Immunotherapy 5:879\u2013893. https:\/\/doi.org\/10.2217\/imt.13.77","journal-title":"Immunotherapy"},{"key":"1751_CR44","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.yexmp.2005.11.004","volume":"80","author":"M De Martinis","year":"2006","unstructured":"De Martinis M, Franceschi C, Monti D, Ginaldi L (2006) Inflammation markers predicting frailty and mortality in the elderly. Exp Mol Pathol 80:219\u2013227. https:\/\/doi.org\/10.1016\/j.yexmp.2005.11.004","journal-title":"Exp Mol Pathol"},{"key":"1751_CR45","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1111\/j.1532-5415.1991.tb04456.x","volume":"39","author":"AD Mooradian","year":"1991","unstructured":"Mooradian AD, Reed RL, Osterweil D, Scuderi P (1991) Detectable serum levels of tumor necrosis factor alpha may predict early mortality in elderly institutionalized patients. J Am Geriatr Soc 39:891\u2013894. https:\/\/doi.org\/10.1111\/j.1532-5415.1991.tb04456.x","journal-title":"J Am Geriatr Soc"},{"key":"1751_CR46","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1111\/j.1365-2265.2007.02853.x","volume":"67","author":"BJ Kim","year":"2007","unstructured":"Kim BJ, Yu YM, Kim EN, Chung YE, Koh JM, Kim GS (2007) Relationship between serum hsCRP concentration and biochemical bone turnover markers in healthy pre- and postmenopausal women. Clin Endocrinol (Oxf) 67:152\u2013158. https:\/\/doi.org\/10.1111\/j.1365-2265.2007.02853.x","journal-title":"Clin Endocrinol (Oxf)"},{"key":"1751_CR47","doi-asserted-by":"publisher","DOI":"10.1016\/j.bonr.2020.100275","volume":"12","author":"T Mawatari","year":"2020","unstructured":"Mawatari T, Ikemura S, Matsui G, Iguchi T, Mitsuyasu H, Kawahara S, Maehara M, Muraoka R, Iwamoto Y, Nakashima Y\u00a0(2020) Assessment of baseline bone turnover marker levels and response to risedronate treatment: data from a Japanese phase III trial. Bone Rep 12:100275. https:\/\/doi.org\/10.1016\/j.bonr.2020.100275","journal-title":"Bone Rep"},{"key":"1751_CR48","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s00198-015-3145-7","volume":"27","author":"KE Naylor","year":"2016","unstructured":"Naylor KE, Jacques RM, Paggiosi M, Gossiel F, Peel NF, McCloskey EV, Walsh JS, Eastell R\u00a0(2016) Response of bone turnover markers to three oral bisphosphonate therapies in postmenopausal osteoporosis: the Trio study. Osteoporos Int 27:21\u201331. https:\/\/doi.org\/10.1007\/s00198-015-3145-7","journal-title":"Osteoporos Int"}],"container-title":["Journal of Bone and Mineral Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00774-026-01751-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00774-026-01751-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00774-026-01751-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T08:27:44Z","timestamp":1791275264000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00774-026-01751-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,6]]},"references-count":48,"alternative-id":["1751"],"URL":"https:\/\/doi.org\/10.1007\/s00774-026-01751-x","relation":{},"ISSN":["0914-8779","1435-5604"],"issn-type":[{"value":"0914-8779","type":"print"},{"value":"1435-5604","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,6]]},"assertion":[{"value":"19 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"NY received a lecture fee from Asahi Kasei Pharma Corporation and TEIJIN PHARMA. KK received a lecture fee from Asahi Kasei Pharma Corporation.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"As this was a systematic review and meta-analysis of previously published studies, ethical approval and patient consent were not required.","order":2,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}